Shots:
- The integration of real-time CGM data into the smart insulin pen app follows the acquisition of Companion Medical’s InPen to the Medtronic portfolio, as of Sept’2020
- The integrated system provides real-time glucose readings alongside insulin dose information giving users everything they need to manage their diabetes through a single smartphone app
- InPen is the first and only FDA-cleared smart2 insulin pen on the market for people on MDI. The InPen app will continue to display information from other compatible CGM systems on a three-hour delay
Click here to read the full press release/ article | Ref: Medtronic | Image: Medical Product Outsourcing
The post Medtronic Launches InPen Integrated with CGM Data for People with Diabetes on MDI first appeared on PharmaShots.
